RxDoctor Payments Data

James Lee, MD

Gastroenterology · Orange, CANPI 1750358735

Payments from drug & device makers

$13,952in general payments, 2019–2025

Across 758 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$906
  • Bristol Myers Squibb$785
  • Johnson & Johnson$696
  • Madrigal Pharmaceuticals$610
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$13,932100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,952 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$252,920
Medicare patients
534
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide80$60,904
VemlidyTenofovir Alafenamide24$34,878
XifaxanRifaximin14$30,779
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates417$23,772
ZenpepLipase/Protease/Amylase16$22,804
Esomeprazole Magnesium232$17,217
Dexlansoprazole DrDexlansoprazole48$15,307
TrulancePlecanatide26$14,812
Mesalamine35$12,137
VoqueznaVonoprazan Fumarate11$9,311
Sucralfate155$7,989
Omeprazole476$7,742
Ursodiol30$5,985
Pantoprazole Sodium534$5,965
AprisoMesalamine12$5,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$4,003$60,90480 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso, Plenvu$2,174$53,28466 claims
GileadVemlidy$262$34,87824 claims
Aimmune Therapeutics, Inc.Zenpep$314$22,80416 claims
Phathom Pharmaceuticals, Inc.Voquezna$220$9,31111 claims
Redhill Biopharma Inc.Movantik$75$5,51914 claims
Ferring Pharmaceuticals Inc.Clenpiq$214$5,03629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →